摘要
In recent years,the global incidence of hepatitis E virus(HEV)has been rising,leading to increased morbidity and mortality associated with hepatitis.Cas13,a CRISPR effector,shows promise as an antiviral agent against singlestranded RNA viruses.Cas13d,a type VI-D effector,exhibits higher efficiency in suppressing RNA viruses compared to other type VI variants.However,its in vivo activity against RNA viruses in mammals remains unknown.
基金
supported by the National Transgenic Major Program of China(No.2016ZX08009-003-006)
Plan 111(No.B12008).
